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Abstract
Introduction: Systemic lupus erythematosus (SLE) is a T and B cell-dependent autoimmune disease characterized
by the appearance of autoantibodies, a global regulatory T cells (Tregs) depletion and an increase in Th17 cells.
Recent studies have shown the multifaceted immunomodulatory effects of vitamin D, notably the expansion of
Tregs and the decrease of Th1 and Th17 cells. A significant correlation between higher disease activity and lower
serum 25-hydroxyvitamin D levels [25(OH)D] was also shown.
Methods: In this prospective study, we evaluated the safety and the immunological effects of vitamin D
supplementation (100 000 IU of cholecalciferol per week for 4 weeks, followed by 100 000 IU of cholecalciferol per
month for 6 months.) in 20 SLE patients with hypovitaminosis D.
Results: Serum 25(OH)D levels dramatically increased under vitamin D supplementation from 18.7±6.7 at day 0 to
51.4±14.1 (p<0.001) at 2 months and 41.5±10.1 ng/mL (p<0.001) at 6 months. Vitamin D was well tolerated and
induced a preferential increase of naïve CD4+ T cells, an increase of regulatory T cells and a decrease of effector
Th1 and Th17 cells. Vitamin D also induced a decrease of memory B cells and anti-DNA antibodies. No
modification of the prednisone dosage or initiation of new immunosuppressant agents was needed in all patients.
We did not observe SLE flare during the 6 months follow-up period.
Conclusions: This preliminary study suggests the beneficial role of vitamin D in SLE patients and needs to be
confirmed in randomized controlled trials.
Introduction
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disease characterized by skin, joint, neurological and
kidney involvement and serositis. Therapeutic manage-
ment depends on the type and severity of organ involve-
ment and includes nonsteroidal anti-inflammatory drugs,
hydroxychloroquine, corticosteroids, and immunosuppres-
sive agents [1]. Nevertheless, long-term suppressive
corticosteroids and/or immunosuppressive agents remain
associated with morbidity and mortality [2]. SLE is a
T and B cell-dependent disease characterized by the
appearance of a variety of autoantibodies, some of which
are pathogenic [1,3]. T cells are needed to initiate and sus-
tain the secretion of antibodies by B cells, in particular
to histones and double-stranded DNA [4]. SLE is also
associated with global depletion of regulatory T cells
(Tregs) [5], an increase in T helper lymphocytes producing
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Vitamin D from the skin and diet is metabolized in the
liver to 25-hydroxyvitamin D (25(OH)D), which is used
to determine a patient’s vitamin D status; 25(OH)D is
metabolized in the kidneys by the enzyme 25-hydroxyvi-
tamin D-1a-hydroxylase (CYP27B1) to its active form,
1,25-dihydroxyvitamin D. Recent studies have shown the
multifaceted immunomodulatory effects in vitro of active
vitamin D (calcitriol or 1,25-dihydroxyvitamin D), which
is the ligand of the vitamin D receptor, notably the
expansion of Tregs, which are able to suppress prolifera-
tion of effector T cells [9], and the decrease of Th1 and
Th17 cells [9,10]. Active vitamin D inhibits B cell activa-
tion and differentiation into plasmablasts and immuno-
globulin production [10-12]. Active vitamin D has also
been shown to inhibit the activation and maturation of
dendritic cells [13]. In addition, studies have shown a
significant correlation between higher SLE activity and
lower serum 25(OH)D levels [13,14]. These findings
provide a rationale for considering vitamin D supplemen-
tation as an immunomodulatory agent for SLE.
We report here on the findings of a preliminary pro-
spective monocenter open-label study designed to assess
the safety and immunological effects of oral vitamin
D supplementation in patients with SLE. We showed that
vitamin D supplementation modulates Tregs and effector
T cell balance by increasing Tregs and decreasing the




This prospective study included consecutive SLE
patients from the Department of Internal Medicine at
Pitié-Salpêtrière Hospital (http://www.clinicaltrials.gov
NCT01413230). Patients were eligible for the study
when they met at least four of the 1997 American Col-
lege of Rheumatology criteria for SLE [15]. Inclusion cri-
teria for the study were as follows: 1) inactive disease or
mild to moderate active disease indicated by a score ≤ 8
in the Safety of Estrogens in Lupus Erythematosus
National Assessment-Systemic Lupus Erythematosus
Disease Activity Index (SELENA-SLEDAI), and 2) stable
dosage of prednisone and/or immunosuppressive agents
for at least 1 and/or 3 months, respectively. Pregnant
patients and those planning pregnancy, and patients
who had previously received B cell-targeted therapy
were excluded. Disease activity was assessed using
SELENA-SLEDAI [16].
Study design
Between 1 September and 31 November 2010, we assessed
24 SLE patients for eligibility (twenty-two women and two
men, mean age ± SD, 31 ± 8 years). Their serum 25(OH)D
level was measured. Hypovitaminosis D was defined as
serum 25(OH)D < 30 ng/mL, while vitamin D sufficiency
was defined as serum levels between 30 and 100 ng/mL
[17]. Those with hypovitaminosis D (< 30 ng/mL) were
placed on the following schedule of oral vitamin D supple-
mentation: 100,000 IU of cholecalciferol per week for
4 weeks, followed by 100,000 IU of cholecalciferol per
month for 6 months. All supplemented patients were
screened before vitamin D supplementation (Day 0, or
D0), and 2 and 6 months (M2 and M6) after the beginning
of vitamin D supplementation. All but four patients
received hydroxychloroquine (200 or 400 mg daily) and/or
oral prednisone (≤ 15 mg/day, median dosage 5 mg/day).
Three patients received a stable dosage of immunosup-
pressive agents. The study was approved by the institu-
tional ethics committee, the Comité de protection des
personnes Ile-de-France VI, in the Pitié-Salpêtrière Hospi-
tal (Paris, France) and informed consent was obtained
from all patients.
At each visit, the SELENA-SLEDAI was recorded.
Routine measurements were made of 25(OH)D levels,
antinuclear antibodies by indirect immunofluorescence
on HEp2 cells (Immunoconcepts, Sacramento CA,
USA), anti-dsDNA antibodies levels by ELISA (DiaSorin,
Saluggia, Italy), complement C3 and C4 levels, complete
blood count, serum creatinine, proteinuria and hema-
turia. Serum 25(OH)D was measured in serum samples
by means of a radioimmunoassay after simple extraction
with acetonitrile, as described previously [18].
The primary endpoint of this study was safety. Safety
endpoints included the occurrence of hypercalcemia,
hyperphosphoremia or lithiasis. Secondary outcomes
included changes from baseline in T cell and B cell
homeostasis, and cytokines and gene expression profiles,
in peripheral blood mononuclear cells (PBMCs), and
clinical efficacy assessment using the SELENA-SLEDAI.
Flow cytometry
PBMC subsets (CD3+, CD4+, CD8+ T lymphocytes, CD19+
B lymphocytes and CD3-CD56+ NK cells) counts (cells/μL)
were established from fresh blood samples using CYTO-
STAT tetraCHROME kits with Flowcount fluorescents
beads as an internal standard and tetra CXP software with
a Navios cytometer according to the manufacturer’s
instructions (Beckman Coulter, Villepinte, France). Subsets
of these cells were analyzed using multicolor flow cytome-
try and monoclonal antibodies (mAbs) directly conjugated
to various fluorescent markers. PBMCs were also stained
with the following conjugated mAbs at predetermined opti-
mal dilutions for 30 minutes at 4°C: CD3-ECD, CD4-PCy7,
CD4-ECD, CD8-PCy7, CD8-APC, CD10-APC, CD16-
FITC, CD19-ECD, CD27-PE, CD28-FITC, CD45RO-FITC,
CD45RA-APC, CD56-PE, HLA-DR-PCy7 (Beckman Coul-
ter), CD25-PE, CD38-PCy7, CD56-FITC, CD62L-FITC,
IgD-FITC (BD Pharmingen, Le-Pont-de-Claix, France),
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CCR7-PE and LAP-PE (R&D systems, Lille, France),
CD127-FITC (eBioscience, Paris, France) and GITR-PE and
CD25-APC (Miltenyi Biotec, Paris, France). Intracellular
detection of FoxP3 and CD152 (CTLA4) was performed on
fixed and permeabilized cells using appropriate buffer
(eBioscience for FoxP3, BD Pharmingen for CD152). Cell
acquisition and analysis by flow cytometry were performed
using a Navios Cytometer (Beckman Coulter). Instrument
setting parameters (gains, compensations, and threshold)
were set with machine software (CXP Software; Beckman
Coulter) in conjunction with calibration beads (Flow-set
beads, Cytocomp kit, and CYTO-TROL Control Cells).
Machine reproducibility was verified with standardized
beads (Flow-check). Data were analyzed with CXP analysis
software and Kaluza software (Beckman Coulter)
For detection of intracellular cytokine production,
PBMCs were stimulated with 50 ng/mL phorbol myristate
acetate (PMA) and 1 mM ionomycin in the presence of
Golgi-Plug (BD Pharmingen) for 4 hours and then stained
with anti-IL-4-FITC, anti-IFN-g-FITC, anti-IL-10-PE
(BD Pharmingen), or anti-IL-17A-Alexa Fluor 647
(eBioscience) after fixation and permeabilization, accord-
ing to the manufacturer’s instructions. Culture super-
natants from PBMCs stimulated in the absence of
Golgi-Plug were harvested and immediately frozen at -80°C.
Statistical analyses
We compared measures taken at baseline (before the
vitamin D supplementation) with those taken at M2 and
M6 after the initiation of vitamin D supplementation,
using the Wilcoxon signed-rank test. All tests were two-
sided with a 0.05 significance level. Graphing and statis-
tical analyses were performed using Prism software
(GraphPad Software, Inc.).
Results
Study design and participants
Out of the 24 patients screened for serum 25(OH)D levels,
20 patients (83%) had hypovitaminosis D and were
included in this prospective study. The baseline character-
istics of the 20 patients are listed in Table 1. All patients
completed the 6 months follow-up period.
Safety and clinical and biological efficacy of vitamin D
supplementation
Serum 25(OH)D levels dramatically increased under vita-
min D supplementation from 18.7 ± 6.7 at D0 to 51.4 ±
14.1 (P < 0.001) at M2 and to 41.5 ± 10.1 ng/mL (P <
0.001) at M6 (Figure 1A). Treatment was safe, with no sig-
nificant increase of serum calcium and phosphorous and
no occurrence of lithiasis. Although not statistically signifi-
cant, disease activity assessed by the SELENA-SLEDAI
slightly decreased from 2.9 ± 2.5 at D0 to 2.6 ± 2.5 at M2
(P = 0.67) and to 1.9 ± 1.8 at M6 (P = 0.16) (Figure 1B).
C3 complement fraction levels remained stable during fol-
low-up, while anti-dsDNA levels decreased from 177 ± 63
at D0 to 124 ± 67 at M2 (P < 0.05) and to 103 ± 36
IU/mL at M6 (P < 0.01) (Figures 1C). No patients required
modification of the prednisone dosage or initiation of new
immunosuppressant agents. We did not observe SLE flare
during the 6 months follow-up period.
Peripheral blood lymphocytes with vitamin D
supplementation
The impact of vitamin D supplementation on the propor-
tion and the absolute number of CD3+ T cells, CD4+ and
CD8+ T cells, CD19+ B cells and CD3-CD56+ NK cells is
shown in Figure 2. The mean proportions and absolute
numbers at baseline were 80 ± 8% and 810 ± 274/mm3
for CD3+ T cells, 42 ± 7% and 412 ± 157/mm3 for CD4+
T cells, 37 ± 12% and 356 ± 128/mm3 for CD8+ T cells,
12 ± 6% and 138 ± 89/mm3 for CD19+ B cells and 6 ±
5% and 61 ± 46/mm3 for CD3-CD56+ NK cells. At M2
and M6, the proportion and absolute number of CD3+
T cells, CD4+ and CD8+ T cells and CD3-CD56+ NK
cells remained stable, while CD19+ B cell frequency and
counts significantly decreased at M2 (P < 0.05 for both)
(Figure 2).
Table 1 Patient characteristics
Characteristics N = 20
Epidemiology
Age, y, mean ± SD 31 ± 8
Female gender, n (%) 20 (100)
Previous SLE manifestations
Skin, n (%) 11 (55)
Joints, n (%) 9 (45)
Serositis, n (%) 4 (20)
Kidney, n (%) 11 (55)
Central nervous system, n (%) 1 (5)
SELENA-SLEDAI at Day 0, mean (range) 2 (0 to 8)
25-Hydroxyvitamin D levels
Mean ± SD, ng/mL 22 ± 11
25(OH)D ≤ 10 ng/mL, n (%) 1 (5)
11 < 25(OH)D ≤ 20 ng/mL, n (%) 11 (55)
21 < 25(OH)D ≤ 30 ng/mL, n (%) 8 (40)
Associated treatments*
Prednisone, n (%) 14 (70)
Prednisone, median, mg/day (range) 5 (0 to 15)
Hydroxychloroquine, n (%) 17 (85)
Azathioprine, n (%) 2 (10)
Mycophenolate mofetil, n (%) 1 (5)
*At the time of the study. SLE: systemic lupus erythematosus; SELENA-SLEDAI:
Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic
Lupus Erythematosus Disease Activity Index; 25(OH)D: 25-hydroxyvitamin D.
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Vitamin D supplementation induces a preferential
increase of naïve CD4+ T cells and a decrease of effector
memory CD8+ T cells and memory B cells
Naïve CD4+ T cells increased in frequency without
reaching the significance level (P = 0.09 and P = 0.10,
respectively) and in absolute number (P = 0.05 and P <
0.01, respectively) at M2 and M6 with vitamin D supple-
mentation, while other CD4+ T cell subsets remained
stable. Effector memory CD8+ T cells decreased in fre-
quency (P = 0.02 and P = 0.01, respectively) but not in
absolute number (P = 0.11 and P = 0.55, respectively) at
M2 and M6 with vitamin D supplementation (Figure 3A).
Using IgD and CD27 surface markers, we also
observed a decrease in IgD-CD27+ class-switched mem-
ory B cell frequency (P < 0.05) and absolute number
(P = 0.06) at M2 and in IgD-CD27- memory B cell fre-
quency (P = 0.11 and P < 0.001, respectively) and abso-
lute number (P < 0.05 and P < 0.01, respectively) at M2
and M6, while IgD+CD27+ marginal zone-like B cell fre-
quency increased at M6 (P < 0.001) (Figure 3B).
Vitamin D supplementation induces a significant increase
of regulatory T cells
The impact of vitamin D supplementation on CD3+CD4+
CD25hiCD127-FoxP3+ Tregs and Treg subsets was
evaluated (Figure 4A). The percentage and absolute count
of Tregs at baseline was 3.5 ± 1.2% and 15 ± 8 cells/μL.
The percentage of Tregs was increased at 4.6 ± 1.3% at
M2 (P <0.001) and 4.3 ± 1.4% at M6 (P <0.01), and the
absolute count of Tregs was increased at 23 ± 14 cells/μL
(P <0.05) and 25 ± 14 cells/μL (P <0.01), respectively
(Figure 4B). Analysis of CD45RA and CD25 expression on
CD4+ T cells revealed that this increase concerned both
resting and activated memory Tregs (Figure 4B). The
increase in Tregs was associated with an increased expres-
sion of molecules associated with Treg suppression (that
is, CTLA4, GITR and LAP) (Figure 4C).
Vitamin D supplementation induces a significant decrease
of effector Th1 and Th17 cells
Decreases were observed in Th1 cells from 16.9 ± 6.7%
at D0 to 11.0 ± 5.1% at M2, and to 13.6 ± 6.5% at M6
(P < 0.01 and P < 0.05, respectively), in IFN-producing
CD8+ T cells from 35.3 ± 13.2% at D0 to 26.8 ± 12.5%
at M2, and to 29.7 ± 13.4% at M6 (P < 0.05 and P =
0.06, respectively), and in Th17 from 2.0 ± 1.1% at D0
to 1.6 ± 0.9% at M2 and to 2.0 ± 1.3% at M6 (P < 0.01
and P = 0.81, respectively) after vitamin D supplementa-
tion. The Th2 cells remained stable during follow-up
(Figure 5).
Figure 1 Safety and clinico-biological efficacy of vitamin D supplementation in SLE patients. Time evolution of serum 25(OH)D levels (A disease
activity assessed by the SLEDAI (B), and anti-dsDNA levels (C). Serum 25(OH)D levels dramatically increased with vitamin D supplementation, while
anti-dsDNA levels decreased. The dotted line in panel A indicates normal values. Box plots indicate median, interquartile ranges, minimum and
maximum values. Histograms indicate mean ± standard error of the mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001 versus Day 0; Wilcoxon test.
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Discussion
No study to date has assessed the in vivo benefit of vitamin
D supplementation in SLE patients. For the first time, we
assessed the safety and the immunological effects of vita-
min D supplementation in patients with SLE. We demon-
strated that vitamin D was safe and induced a decrease of
memory B cells, an increase of Tregs and a decrease of
effector Th1 and Th17 cells.
First, we confirmed the high frequency of hypovitami-
nosis D in SLE patients. Recent studies have highlighted
vitamin D insufficiency in SLE patients, with approxi-
mately 65% of the patients showing serum 25(OH)D
levels < 30 ng/mL [19-21]. In the present study, we
aimed to reach the recommended serum 25(OH)D
ranges for bone metabolism, that is, 30 to 80 ng/mL,
within the first 2 months. The schedule of vitamin D
administration that we choose included a first phase of
intensive supplementation for one month, followed by a
maintenance phase. Regarding the evolution of serum
levels of 25(OH)D, calcium and phosphorous and the
occurrence of clinical events, this regimen was effective
and safe. We included only SLE patients with low disease
activity (SLEDAI ≤ 8) because we wanted to determine
the specific effects of vitamin D in the absence of initia-
tion or modification of associated therapy, such as an
increase of the prednisone dosage or the use of immuno-
suppressive agents.
We demonstrated that vitamin D supplementation
induced a beneficial effect in vivo on the perturbations of
B cell and T cell homeostasis associated with SLE, by
increasing Tregs and decreasing Th17 and Th1 cells, and
memory B cells. Interestingly, the increase of Tregs con-
cerned both resting Tregs and activated memory Tregs
according to CD45RA and CD25 expression [22]. Our
findings are supported by recently reported in vitro stu-
dies. 1,25(OH)2 vitamin D3, the active form of vitamin D,
was shown to exert a marked inhibitory effect on adap-
tive immune cells, by inhibiting the T cell proliferation
[23,24], the expression of IL-2 [24,25] and IFN-g mRNA
and protein in T cells [9,26,27], while promoting Th2-cell
responses in vitro [28]. In our in vivo study, we did not
observe a significant increase of Th2 cells under vitamin
Figure 2 Evolution of peripheral blood lymphocytes with vitamin D supplementation. Time evolution of the proportion and the absolute
number of CD3+ T cells, CD4+ and CD8+ T cells, CD19+ B cells and CD3-CD56+ NK cells. At 2 and 6 months, the proportion and absolute
number of CD3+ T cells, CD4+ and CD8+ T cells and CD3-CD56+ NK cells remained stable, while the CD19+ B cell frequency and count
significantly decreased at 2 months. Mean ± standard error of the mean (SEM) is shown. *P < 0.05 versus Day 0; Wilcoxon test.
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D supplementation, since this T cell subset remains
stable during follow-up. 1,25(OH)2 vitamin D3 was also
shown to inhibit Th17 responses, probably owing to its
capacity to inhibit IL-23 production [9,29], and to induce
the differentiation and/or expansion of FoxP3+ Tregs and
an increased expression of CTLA4 [9,30-32]. Finally, we
observed a decrease of IgD-CD27+ and IgD-CD27-
memory B cells and a decrease of anti-dsDNA autoanti-
body levels in vitamin D-treated patients. Consistent with
these findings, 1,25(OH)2 vitamin D3 was shown to
decrease B cell proliferation, plasma-cell differentiation
and IgG secretion in vitro [12,23]. The mechanisms by
which 1,25(OH)2 vitamin D3 exerts its immunomodula-
tory effect on B cells remains unclear.
Figure 3 Vitamin D supplementation induces a preferential increase of naïve CD4+ T cells and a decrease of memory B cells. Peripheral
blood mononuclear cells (PBMCs) in the lymphocyte light-scatter gate were analyzed for T cell subsets using CD3, CD4, CD45RA and CD62L staining,
and for B cell subsets using CD19, CD27 and IgD staining. (A) Time evolution of CD4+ and CD8+ T cell subsets. The T cell population includes naive (N;
CD45RA+CD62L+), central memory (CM; CD45RA-CD62L+), effector memory and effector (EM; CD45RA-CD62L-), and terminally differentiated effector
(TE; CD45RA+CD62L-). (B) Time evolution of CD19+ B cell subsets. The B cell population includes naive (N; IgD+CD27-), marginal zone-like (MZ; IgD
+CD27+), class-switched memory (CS IgD-CD27+), and IgD-CD27- B cells. Peripheral blood naïve CD4+ T cells increased and IgD-CD27- memory B cells
decreased under vitamin D supplementation. Mean ± standard error of the mean (SEM) is shown. *P < 0.05, **P < 0.01, ***P < 0.001 versus Day 0;
Wilcoxon test.
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Although too preliminary to be presented in the
present study, we have performed a transcriptome
analysis of PBMCs at D0 versus M2 after vitamin D
supplementation on ten randomly selected patients, in
order to provide additional insights into the immuno-
logical effects of vitamin D in SLE (Additional file 1).
Using independent component analysis (ICA) [33] and
gene set enrichment analysis (GSEA) dataset [34,35],
Figure 4 Vitamin D supplementation induces a significant increase of regulatory T cells. (A) Peripheral blood mononuclear cells (PBMCs) in
the lymphocyte light-scatter gate were analyzed for CD3, CD4, CD25, CD127, CD45RA and FoxP3 staining. Regulatory T cells (Tregs), resting Tregs
(rTregs) and activated memory Tregs (aTregs) were defined as CD3+CD4+CD25hiCD127-FoxP3+ cells, CD3+CD4+CD25++CD45RA+ cells and CD3+CD4
+CD25+++CD45RA- cells, respectively. (B) Time evolution of peripheral blood Tregs, rTregs and aTregs in percentage and absolute number. (C) Time
evolution of CTLA4, GITR and LAP expression by Tregs. Peripheral blood Tregs, rTregs and aTregs increased under vitamin D supplementation, as did
the expression of molecules associated with suppression of Tregs. Mean ± standard error of the mean (SEM) is shown in panel B. Box plots in panel C
indicate median, interquartile ranges, minimum and maximum values. *P < 0.05, **P < 0.01, ***P < 0.001 versus Day 0; Wilcoxon test.
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we identified 48 molecular signatures that were differ-
entially expressed between D0 and M2, with 34 up-
and 14 down-regulated signatures (see Figure S1
inAdditional file 1. This preliminary finding suggests
an effect of vitamin D supplementation on the
immune system. Among the identified signatures, we
observed the down-regulation of RNA polymerase
functions and histone expression and the up-regula-
tion of the TP53/CDKN1A-related pathway that repre-
sent interesting pathways to explore in the future, owing
to their possible involvement with a decrease in the accu-
mulation of autoantigens and the activation and prolifera-
tion of autoreactive T and B lymphocytes. Also, the up-
regulation of the TP53/CDKN1A-related pathway is inter-
esting because CDKN1A is a potent cyclin-dependent
kinase inhibitor that functions as a regulator of cell cycle
progression [36].
Conclusions
Vitamin D supplementation provides beneficial immu-
nological effects in patients with SLE, with a decrease of
memory B cells and effector T cells and an increase of
regulatory T cells. Our results must be interpreted with
caution in the absence of well-designed randomized
controlled trials, particularly for a relevant clinical end-
point. In addition, we focused on the immunological
effects of vitamin D after two months and six months of
supplementation, but earlier time points should bring
additional information, particularly for gene expression
analysis, calling for further studies.
Significance and innovation
Vitamin D supplementation using 100,000 IU of cholecal-
ciferol per week for 4 weeks, followed by 100,000 IU of
cholecalciferol per month for 6 months, was well tolerated.
Vitamin D induced a preferential increase of naïve CD4+
T cells, an increase of regulatory T cells, a decrease of
effector Th1 and Th17 cells, and a decrease of memory
B cells and anti-DNA antibodies.
This preliminary study suggests a beneficial role of
vitamin D in SLE patients and needs to be confirmed in
randomized controlled trials.
Figure 5 Vitamin D supplementation induces a significant decrease in Th1 and Th17 cells. Peripheral blood mononuclear cells (PBMCs)
were stimulated for 4 hours with Phorbol myristate acetate (PMA) and ionomycin. After gating on CD3+ T cells, frequencies of IFN-g-producing
CD4+ (Th1) and CD8+ T cells, IL-17A-producing CD4+ T cells (Th17) and IL-4-producing CD4+ T cells (Th2) were analyzed with vitamin D
supplementation. Th1, IFN-g-producing CD8+ T cells and Th17 cells decreased after 2 months of vitamin D supplementation. Mean ± standard
error of the mean (SEM) is shown. *P < 0.05, **P < 0.01, ***P < 0.001 versus Day 0; Wilcoxon test.
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Additional material
Additional file 1: Microarray gene expression profile analysis. This
file contains additional material and a methods section that describes
microarray gene expression profile analysis, and Figure S1 that illustrates
clustering analysis of significant modulated signatures in patients at
month 2 compared to baseline.
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